Daniel Patterson

Board Member

Dan Patterson is Vice President, Head of CMC, Biologics and Gene Therapies at Roivant, where he plays an active role in evaluating in-licensing opportunities and supporting manufacturing activities for newly created Vants. Prior to joining Roivant in 2017, Dr. Patterson was Vice President of CMC at Cempra, Inc. where he led development activities for an antibiotic in late phase development for community acquired bacterial pneumonia.

Earlier in his career, he worked for 14+ years in the Product Development Group at GlaxoSmithKline supporting CMC programs in all phases of development including leading the development of the commercial manufacturing process for Tivicay (dolutegravir) for treatment of HIV. Throughout his career, he has focused on development of efficient, cost-effective manufacturing processes to allow for wide access to medicines. Dr. Patterson received a B.A. in Chemistry from Williams College, and a Ph.D in Chemistry from Stanford University.